Amiodarone to Prevent Recurrence of Atrial Fibrillation

Background The restoration and maintenance of sinus rhythm is a desirable goal in patients with atrial fibrillation, because the prevention of recurrences can improve cardiac function and relieve symptoms. Uncontrolled studies have suggested that amiodarone in low doses may be more effective and safer than other agents in preventing recurrence, but this agent has not been tested in a large, randomized trial. Methods We undertook a prospective, multicenter trial to test the hypothesis that low doses of amiodarone would be more efficacious in preventing recurrent atrial fibrillation than therapy with sotalol or propafenone. We randomly assigned patients who had had at least one episode of atrial fibrillation within the previous six months to amiodarone or to sotalol or propafenone, given in an open-label fashion. The patients in the group assigned to sotalol or propafenone underwent a second randomization to determine whether they would receive sotalol or propafenone first; if the first drug was unsuccessfu...

[1]  P. Vardas,et al.  Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. , 1998, The American journal of cardiology.

[2]  M. Janse,et al.  Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials , 1997, The Lancet.

[3]  E. Braunwald.  Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. , 1997, The New England journal of medicine.

[4]  A. Ciampi,et al.  Pilot study and protocol of the Canadian Trial of Atrial Fibrillation (CTAF). , 1997, The American journal of cardiology.

[5]  C. January,et al.  Adverse effects of low dose amiodarone: a meta-analysis. , 1997, Journal of the American College of Cardiology.

[6]  S. Hohnloser,et al.  Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. , 1996, The American journal of cardiology.

[7]  W. Stevenson,et al.  Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. , 1995, The American journal of cardiology.

[8]  Crijns,et al.  Functional capacity before and after cardioversion of atrial fibrillation: a controlled study. , 1994, British heart journal.

[9]  W. Stevenson,et al.  Low-dose amiodarone for atrial fibrillation. , 1993, The American journal of cardiology.

[10]  E. Antman,et al.  Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. , 1993, The American journal of cardiology.

[11]  R. Kronmal,et al.  Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. , 1992, Journal of the American College of Cardiology.

[12]  E L Pritchett,et al.  Management of atrial fibrillation. , 1992, The New England journal of medicine.

[13]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[14]  H. Crijns,et al.  Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. , 1991, The American journal of cardiology.

[15]  W. Wilkinson,et al.  Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. , 1991, Annals of internal medicine.

[16]  S. Juul-Möller,et al.  Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. , 1990 .

[17]  E. Antman,et al.  Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. , 1990, Circulation.

[18]  I. V. Van Gelder,et al.  Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. , 1989, The American journal of cardiology.

[19]  E. Pritchett,et al.  Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. , 1989, Circulation.

[20]  S. Connolly,et al.  Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. , 1989, The American journal of cardiology.

[21]  D. Roy,et al.  Doppler echocardiographic predictors of recurrence of atrial fibrillation after cardioversion. , 1988, The American journal of cardiology.

[22]  E. Antman,et al.  Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. , 1988, Journal of the American College of Cardiology.

[23]  D. McDevitt,et al.  Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem. , 1988, European heart journal.

[24]  B. Lown,et al.  Side effects and complications of amiodarone therapy. , 1985, American heart journal.

[25]  W. Kannel,et al.  Epidemiologic features of chronic atrial fibrillation: the Framingham study. , 1982, The New England journal of medicine.

[26]  L E Hinkle,et al.  Clinical Classification of Cardiac Deaths , 1982, Circulation.

[27]  G Klein,et al.  Alterations in Cardiac Function Immediately Following Electrical Conversion of Atrial Fibrillation to Normal Sinus Rhythm , 1968, Circulation.

[28]  H. Mcintosh,et al.  The Changes in Cardiac Output with Reversion of Atrial Fibrillation to Sinus Rhythm , 1965, Circulation.

[29]  E. Vitolo,et al.  Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. , 1981, Acta cardiologica.